Skip to main content
Journal cover image

Opioid treatment program and community pharmacy collaboration for methadone maintenance treatment: results from a feasibility clinical trial.

Publication ,  Journal Article
Wu, L-T; John, WS; Morse, ED; Adkins, S; Pippin, J; Brooner, RK; Schwartz, RP
Published in: Addiction
February 2022

BACKGROUND AND AIMS: Pharmacy administration and dispensing of methadone for methadone maintenance treatment (MMT) can expand treatment access for opioid use disorder (OUD). This study investigated the feasibility and acceptability of a novel model permitting an opioid treatment program (OTP) physician to prescribe methadone for OUD treatment through collaboration with a partnered pharmacy. DESIGN: Non-randomized, single-arm, open-label feasibility trial. SETTING: One OTP and one community pharmacy in the United States. PARTICIPANTS: One OTP physician, two pharmacists and 20 MMT patients receiving between six and 13 take-home methadone doses at 5-160 mg/day. INTERVENTION: Patients' methadone administration and dispensing of take-home doses was transferred from the OTP to the pharmacy for 3 months. MEASUREMENTS: Primary outcome was medication adherence. Secondary outcomes were recruitment, treatment retention, substance use, counseling attendance at the OTP, pharmacist prescription drug monitoring program (PDMP) use, safety and satisfaction. FINDINGS: Of 29 patients eligible at pre-screen, 20 patients (69%) enrolled into the study. Recruitment occurred from 6 August 2020 to 10 October 2020. Treatment retention rate at month 3 was 80% (16 of 20). Two participants returned early to the OTP because of a work/schedule change, one due to pregnancy and one following a non-study-related hospitalization. Medication adherence among 16 patients who were retained was 100%. Intervention fidelity was 100%. All participants attended random call-back visits. None showed evidence of tampering/diversion of methadone. Pharmacists checked the PDMP at all visits. All participants attended psychosocial counseling as planned. There were no positive urine screens for illicit opioid use and no study-related adverse events. All participants endorsed 'pharmacy is the right location for receiving methadone for MMT', 88% endorsed 'convenient or very convenient to receive methadone at the pharmacy' and 88% were satisfied or very satisfied with the quality of treatment offered. CONCLUSIONS: This feasibility trial has found pharmacy administration and dispensing of physician-prescribed methadone for methadone maintenance treatment to be feasible and acceptable.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Addiction

DOI

EISSN

1360-0443

Publication Date

February 2022

Volume

117

Issue

2

Start / End Page

444 / 456

Location

England

Related Subject Headings

  • Substance Abuse
  • Pharmacy
  • Pharmacies
  • Opioid-Related Disorders
  • Opiate Substitution Treatment
  • Methadone
  • Humans
  • Feasibility Studies
  • Analgesics, Opioid
  • 5203 Clinical and health psychology
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Wu, L.-T., John, W. S., Morse, E. D., Adkins, S., Pippin, J., Brooner, R. K., & Schwartz, R. P. (2022). Opioid treatment program and community pharmacy collaboration for methadone maintenance treatment: results from a feasibility clinical trial. Addiction, 117(2), 444–456. https://doi.org/10.1111/add.15641
Wu, Li-Tzy, William S. John, Eric D. Morse, Steve Adkins, Jennifer Pippin, Robert K. Brooner, and Robert P. Schwartz. “Opioid treatment program and community pharmacy collaboration for methadone maintenance treatment: results from a feasibility clinical trial.Addiction 117, no. 2 (February 2022): 444–56. https://doi.org/10.1111/add.15641.
Wu L-T, John WS, Morse ED, Adkins S, Pippin J, Brooner RK, et al. Opioid treatment program and community pharmacy collaboration for methadone maintenance treatment: results from a feasibility clinical trial. Addiction. 2022 Feb;117(2):444–56.
Wu, Li-Tzy, et al. “Opioid treatment program and community pharmacy collaboration for methadone maintenance treatment: results from a feasibility clinical trial.Addiction, vol. 117, no. 2, Feb. 2022, pp. 444–56. Pubmed, doi:10.1111/add.15641.
Wu L-T, John WS, Morse ED, Adkins S, Pippin J, Brooner RK, Schwartz RP. Opioid treatment program and community pharmacy collaboration for methadone maintenance treatment: results from a feasibility clinical trial. Addiction. 2022 Feb;117(2):444–456.
Journal cover image

Published In

Addiction

DOI

EISSN

1360-0443

Publication Date

February 2022

Volume

117

Issue

2

Start / End Page

444 / 456

Location

England

Related Subject Headings

  • Substance Abuse
  • Pharmacy
  • Pharmacies
  • Opioid-Related Disorders
  • Opiate Substitution Treatment
  • Methadone
  • Humans
  • Feasibility Studies
  • Analgesics, Opioid
  • 5203 Clinical and health psychology